Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Smith & Nephew Plc
  6. News
  7. Summary
    SN.   GB0009223206


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Smith & Nephew : +Nephew announces remote Physical Therapy functionality, expanding its ARIA Care Management Platform for ASCs

10/21/2020 | 07:57am EDT

Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, announces key tele-PT assets for its ARIA digital care management platform.

ARIA Home PT, a remote physical therapy module will launch in early 2021, with a telehealth module planned for release shortly afterwards.

These modules will expand Smith+Nephew's suite of digital health offerings and underscores the company's continued investment in its Positive Connections program supporting Ambulatory Surgery Center (ASC) customers.

ARIA Home PT will utilize an on-screen avatar 'coach' and remote monitoring to guide patients through post-acute physical therapy at home. The avatar coaches patients through their prescribed program utilizing 3D motion-capture technology to measure movement and capture rehabilitation metrics critical to patient recovery. These sessions occur in combination with live tele-visits with licensed physical therapists. The ARIA Home PT equipment is shipped directly to the patient's home and requires no wearable technology by the patient user.

An online library of exercises is paired with personalized virtual visits with licensed physical therapists to promote preventive and rehabilitative care of common orthopaedic conditions such as knee osteoarthritis and rotator cuff tears. ARIA Home PT may be of particular interest to self-insured employers and third-party administrators to supplement their existing employee benefits and population health offerings while managing costs.

The modules aim to expand access to care between patients and PT practices and are designed to promote patient education, adherence and satisfaction.

'We have listened to our ASC customers, and their resounding message has been that the anticipated migration toward same-day surgery and a need for digital health solutions has been hastened in recent months,' said Laura Rector, Vice President for Ambulatory Surgery Centers at Smith+Nephew. 'Patients and providers are seeking new ways to provide healthcare remotely, and our tele-PT asset integrations into ARIA will help further facilitate the ongoing shift of site of care in orthopaedics pre and post- operatively. It's a timely addition to our Positive Connections toolkit.'

Launched in August 2020, ARIA is a connected care solution designed to make clinical staff more efficient, streamline care decisions and lead patients to a life unlimited.


David Snyder

Tel: +1 978-749-1440

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,500+ employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.1 billion in 2019. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as 'aim', 'plan', 'intend', 'anticipate', 'well-placed', 'believe', 'estimate', 'expect', 'target', 'consider' and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about SMITH & NEPHEW PLC
07/29European ADRs Move Higher in Thursday Trading
07/29SMITH & NEPHEW : Keeps FY21 Outlook As Profit, Revenue Climb In H1
07/29SMITH & NEPHEW : revenues grew by almost 50 per cent since last quarter
07/29Smith & Nephew Swung to 1st Half Pretax Profit; Backs Guidance
07/29SMITH & NEPHEW : +Nephew Second Quarter and First Half 2021 Results
07/22SMITH & NEPHEW : Study shows Smith+Nephew's REGENETEN Bioinductive Implant sets ..
07/21SMITH & NEPHEW : Says Regeneten Bioinductive Implant Improves Shoulder Function ..
07/21SMITH & NEPHEW : Study shows Smith+Nephew's REGENETEN◊ Bioinductive Implant ..
07/21Smith+Nephew Announces Study Results Showing Patients Treated with Just its R..
07/19SMITH & NEPHEW : Commission pursuant to Rule 12g3-2 (b) under the Securities Exc..
More news
Financials (USD)
Sales 2021 5 370 M - -
Net income 2021 464 M - -
Net Debt 2021 1 850 M - -
P/E ratio 2021 39,3x
Yield 2021 1,81%
Capitalization 17 953 M 17 961 M -
EV / Sales 2021 3,69x
EV / Sales 2022 3,43x
Nbr of Employees 17 914
Free-Float 99,1%
Duration : Period :
Smith & Nephew Plc Technical Analysis Chart | SN. | GB0009223206 | MarketScreener
Technical analysis trends SMITH & NEPHEW PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 20,45 $
Average target price 23,72 $
Spread / Average Target 16,0%
EPS Revisions
Managers and Directors
Roland D. Diggelmann Chief Executive Officer & Non-Executive Director
Anne-Francoise Nesmes Chief Financial Officer & Executive Director
Roberto Quarta Chairman
Vasant Padmanabhan President-Research & Development
Mark Gladwell President-Global Operations & Business Services
Sector and Competitors